Abbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance

/PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2022. Second-quarter sales of $11.3 billion...

Related Keywords

China ,Robertb Ford , ,Linkedin ,Drug Administration ,Core Laboratory Diagnostics ,Sales In Core Laboratory ,European Union Medical Device ,Facebook ,Abbott Laboratories ,Core Laboratory ,Pediatric Nutrition ,Adult Nutrition ,Molecular Diagnostics ,Emerging Markets ,Medical Devices ,Diabetes Care ,Freestyle Libre ,Aristocrats Index ,Investor Relations ,Private Securities Litigation Reform Act ,Caution Concerning Forward Looking ,Annual Report ,Abbott Diabetes ,Consolidated Statement ,Quarter Ended June ,Operating Cost ,Earnings Excluding Specified Items ,Common Share ,Specified Items ,Common Shares ,Dilutive Common Stock Options ,Diluted Earnings ,Half Ended June ,Financial Information ,Gross Margin ,European Union ,Medical Device ,Vitro Diagnostics Medical Device ,Abbott ,Household ,Onsumer Amp Cosmetics ,Retail ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Earnings Forecasts Amp Projections ,Earnings ,